Abstract
Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
